Clinical trials: Primary Headache Disorders
Migraine
A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches
The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine.
- Trial name
- NCT00210912
- Testing
- topiramate
- Volunteers
- 328 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine
A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults
PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced…
- Trial name
- NCT01981499
- Testing
- PF-05180999, 120 mg MR PF-05180999, 360 mg MR PF-05180999
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Preventing Migraine Headaches in Children
The purpose of this study is to assess the safety and efficacy of topiramate as compared to placebo in preventing migraines in children.
- Trial name
- NCT00237302
- Testing
- topiramate
- Volunteers
- 162 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Migraine
DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study
The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.
- Trial name
- NCT00640965
- Testing
- DP-VPA
- Where
- 6 sites in Israel
- Volunteers
- 40 people
- Sponsor
- D-Pharm Ltd.
Migraine
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
- Trial name
- DRAGON (NCT03867201)
- Testing
- Erenumab
- Where
- 63 sites in China, India and 7 more
- Volunteers
- 557 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
The Prolonged Use of Topiramate for Preventing Migraine Headaches
The purpose of this study is to evaluate the safety and effectiveness (beyond 6 months) of individualized doses (100 to 200 milligrams) of topiramate for the prevention of migraine headaches over a period of 26 weeks.
- Trial name
- PROMPT (NCT00216619)
- Testing
- Topiramate
- Where
- 68 sites in Austria, Belgium and 18 more
- Volunteers
- 834 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
PMS, Menstrual Cramp
A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome
This virtual, randomized, placebo-controlled clinical trial evaluates the effectiveness of a PMS capsule and PMS gummy in alleviating premenstrual syndrome symptoms over 12 weeks.
- Conditions
- PMS, Menstrual Cramp, Mood Change
- Trial name
- NCT06763809
- Testing
- PMS Capsule, PMS Gummy
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Semaine Health
Migraine
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
- Trial name
- NCT07645924
- Testing
- Elismetrep
- Where
- 113 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- TriGemX Bio, Inc.
Migraine Headache
A Study of LY2951742 in Participants With Migraine
To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in migraineurs with or without aura during 3 months of treatment.
- Trial name
- NCT01625988
- Testing
- LY2951742
- Where
- 37 sites in United States
- Volunteers
- 218 people
- Sponsor
- Eli Lilly and Company
Migraines
A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250
A trial to assess the efficacy, safety, tolerability and effect of a drug (code name TRV250) given as an injection to subjects who have received an injection of a drug called glyceryl trinitrate (GTN) which is clinically known to…
- Trial name
- NCT04201080
- Testing
- Part A: TRV250-20mg/ml, Part B: TRV250 Dose 1, Part B: TRV250 Dose 2
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Trevena Inc.
Migraine
Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
The purpose of this study is: To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet…
- Trial name
- NCT01507610
- Testing
- Sumatriptan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Optinose US Inc.
Episodic Cluster Headache
Intranasal Civamide for Episodic Cluster Headache
This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active…
- Trial name
- NCT00069082
- Testing
- Civamide (Zucapsaicin), Sodium Chloride
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Winston Laboratories
Migraine
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
The purpose of this study is to determine the central 5-HT1B receptor occupancy of ZOMIG® Rapimelt (zolmitriptan) in healthy male volunteers.
- Trial name
- NCT01085123
- Testing
- Rapimelt, [11C]AZ10419369
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Migraine
Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks
National clinical trials, phase III, randomized, open, parallel, study of superiority, in which three hundred thirty-six (336) participants of both sexes, aged between 18 and 65 years will be randomly allocated to one of two…
- Trial name
- NCT02582996
- Testing
- Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide., Acetaminophen
- Where
- 6 sites in Brazil
- Volunteers
- 336 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Chronic Cluster Headache
Cephalic Vascular Recording Upon SPG Stimulation
Hypothesis: Stimulation of the SPG at high frequencies (50-200Hz) is believed to cause a physiological parasympathetic block which decreases VMCA oxyHb concentration and cephalic vessel diameter.
- Trial name
- NCT01359631
- Volunteers
- 7 people
- Sponsor
- Autonomic Technologies, Inc.
Migraine
Nerivio Efficacy Under High-Frequency Use
This is a Post-marketing study investigating the impact of frequant usage with Nerivio on the safety profile of Remote Electrical Neuromodulation (REN) for the treatment of migraine.
- Trial name
- NCT07336056
- Testing
- Nerivio (REN device)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Theranica
Migraine
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity.
- Trial name
- EMPRESS (NCT05158894)
- Where
- 2 sites in United States, Canada
- Volunteers
- 1,884 people
- Sponsor
- AbbVie
Migraine
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines.
- Trial name
- NCT05133323
- Testing
- Lu AG09222
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 237 people
- Sponsor
- H. Lundbeck A/S
Migraine
A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with…
- Trial name
- NCT03988088
- Testing
- Lasmiditan
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company